Olfactory dysfunction in corticobasal syndrome (CBS) represents an important but understudied non-motor manifestation that provides insights into disease pathophysiology and differential diagnosis. While classically associated with Parkinson's disease and Dementia with Lewy Bodies, olfactory function in CBS demonstrates a distinct pattern reflecting its unique pathological substrate.
¶ Prevalence and Clinical Characteristics
Olfactory dysfunction in CBS is less prominent compared to alpha-synucleinopathies, reflecting the tau-predominant pathology of most CBS cases.
| Feature |
CBS |
PD |
DLB |
PSP |
| Olfactory Loss Prevalence |
20-35% |
70-90% |
80-95% |
15-30% |
| Severity |
Mild-Moderate |
Moderate-Severe |
Severe |
Mild |
| Onset Relative to Motor |
Variable |
Pre-motor common |
Concurrent |
Variable |
| Olfactory Bulb Pathology |
Variable |
Severe |
Severe |
Variable |
- Prevalence: Approximately 20-35% of CBS patients demonstrate olfactory dysfunction on standardized testing (UPSIT < 15th percentile)
- Severity: When present, olfactory deficits are typically mild to moderate, rarely reaching the severe range seen in DLB
- Temporal Pattern: Olfactory loss may develop concurrently with or after motor symptoms; pre-motor olfactory loss is less characteristic than in PD
- Anosmia: Complete anosmia is rare in CBS, occurring in fewer than 10% of affected individuals
The relatively preserved olfactory function in CBS compared to alpha-synucleinopathies reflects differences in pathological involvement of olfactory structures.
flowchart TD
A["CBS Pathology"] --> B["Olfactory Bulb Involvement"]
A --> C["Olfactory Tract Degeneration"]
A --> D["Primary Olfactory Cortex"]
B --> E{"Tau vs Alpha-Syn"}
C --> E
D --> E
E -->|"Tau Predominant"| F["Mild-Moderate Loss"]
E -->|"Alpha-Syn Predominant"| G["Severe Loss"]
F --> H["20-35% Prevalence"]
G --> I["70-95% Prevalence"]
-
Olfactory Bulb Pathology
- Tau pathology (neurofibrillary tangles, astrocytic plaques) in olfactory bulb varies widely
- Less severe than in Lewy body disease where olfactory bulb is heavily involved
- Glial pathology in olfactory bulb correlates with disease duration
-
Olfactory Tract and Primary Olfactory Cortex
- Post-mortem studies show variable involvement of anterior olfactory nucleus
- Cortical involvement correlates with disease severity when present
- Less consistent involvement than in PD/DLB
-
Tau isoform patterns
- 4R tau (predominant in CBS) shows different olfactory involvement compared to 3R/4R mixed tau in AD
- Astrocytic plaques in olfactory bulb have been documented in CBD cases
Olfactory testing can assist in the differential diagnosis of atypical parkinsonian syndromes.
| Condition |
Expected Olfactory Function |
Utility |
| CBS |
Usually preserved or mildly reduced |
Moderate |
| PSP |
Usually preserved or mildly reduced |
Low-Moderate |
| PD |
Severely reduced |
High |
| DLB |
Severely reduced |
Very High |
| MSA |
Variable, often reduced |
Moderate |
- Screening Tool: Olfactory testing (UPSIT, SS-16) can help differentiate CBS from PD when severe olfactory loss is present
- Pathological Prediction: Preserved olfaction suggests non-Lewy body pathology
- Complementary Biomarker: When combined with other markers (MRI, FDG-PET), olfactory testing adds diagnostic confidence
¶ Standardized Olfactory Tests
-
University of Pennsylvania Smell Identification Test (UPSIT)
- 40-item scratch-and-sniff test
- Most validated instrument for olfactory assessment
- Score < 15th percentile indicates dysfunction
-
Sniffin' Sticks Test
- 16-item screening version available
- Threshold, discrimination, and identification subtests
- Extended version (112 items) for research
-
Cross-Cultural Smell Identification Test (CC-SIT)
- 12-item version
- Useful for brief clinical screening
| UPSIT Score |
Interpretation |
CBS Correlation |
| >34 |
Normosmia |
Common |
| 19-33 |
Mild dysfunction |
Possible |
| 13-18 |
Moderate dysfunction |
Less common |
| <13 |
Severe dysfunction/Anosmia |
Rare |
Both CBS and PSP show relatively preserved olfactory function compared to alpha-synucleinopathies:
- Similar prevalence: 15-35% in both conditions
- Pathological basis: Both show 4R tau-predominant pathology with variable olfactory involvement
- Differential value: Limited between CBS and PSP
- AD: Moderate olfactory dysfunction (40-60% prevalence), correlates with Braak stage
- CBS: Lower prevalence (20-35%), more variable correlation with disease severity
- Baseline Testing: Perform olfactory testing at diagnosis to establish baseline
- Serial Monitoring: Annual reassessment tracks disease progression
- Integration: Combine with other non-motor assessments (autonomic, sleep, neuropsychiatric)
- Fire Safety: Patients with significant olfactory loss require educational fire safety counseling
- Food Safety: Reduced ability to detect smoke, gas leaks, spoiled food
- Social Impact: Anosmia affects quality of life and nutritional status
- Environmental Safety: Smoke detectors, gas leak detectors with visual/auditory alerts
- Nutritional Counseling: Emphasis on visual presentation of food, seasoning adjustments
- Referral: Consider referral to otolaryngology for evaluation of treatable causes
- Olfactory Bulb Imaging: High-resolution MRI to assess olfactory bulb volume changes
- Olfactory Event-Related Potentials: Neurophysiological markers of olfactory processing
- Longitudinal Studies: Tracking olfactory change across disease progression
- Pathological Correlation: Post-mortem studies correlating olfactory pathology with antemortem function
Olfactory dysfunction may serve as:
- Secondary biomarker: When combined with established markers
- Disease stage marker: Reflecting disease burden in olfactory regions
- Therapeutic target: Direct drug delivery via olfactory route being explored